Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Volitionrx (VNRX) Short term Debt (2019 - 2025)

Historic Short term Debt for Volitionrx (VNRX) over the last 8 years, with Q3 2025 value amounting to $913582.0.

  • Volitionrx's Short term Debt fell 533.04% to $913582.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $913582.0, marking a year-over-year decrease of 533.04%. This contributed to the annual value of $860223.0 for FY2024, which is 2873.09% down from last year.
  • Per Volitionrx's latest filing, its Short term Debt stood at $913582.0 for Q3 2025, which was down 533.04% from $1.0 million recorded in Q2 2025.
  • Over the past 5 years, Volitionrx's Short term Debt peaked at $1.3 million during Q1 2022, and registered a low of $759507.0 during Q3 2021.
  • Over the past 5 years, Volitionrx's median Short term Debt value was $1.1 million (recorded in 2022), while the average stood at $1.0 million.
  • Per our database at Business Quant, Volitionrx's Short term Debt surged by 4018.84% in 2022 and then plummeted by 2873.09% in 2024.
  • Over the past 5 years, Volitionrx's Short term Debt (Quarter) stood at $797855.0 in 2021, then surged by 33.7% to $1.1 million in 2022, then rose by 13.15% to $1.2 million in 2023, then fell by 28.73% to $860223.0 in 2024, then increased by 6.2% to $913582.0 in 2025.
  • Its Short term Debt stands at $913582.0 for Q3 2025, versus $1.0 million for Q2 2025 and $862475.0 for Q1 2025.